Physician profile
Jane Block
NPI 1750398608
$4,710.99
in general payments reported to CMS, 2019-2025
34 companies · $720 in 2025
The $720 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,124 · 2022: $1,025 · 2023: $948 · 2024: $893 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,114.13 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $480.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $403.82 | 2022-2025 | |
| Lilly USA, LLC | $378.29 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Neuronetics, INC. | $246.10 | 2025 | Neurostar Tms Therapy System |
| Amgen INC. | $219.12 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $191.14 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $174.57 | 2021-2024 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $157.53 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $154.39 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $151.09 | 2022-2025 | Quviviq, Quviviq |
| Exact Sciences Corporation | $144.66 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $138.63 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Glaxosmithkline, LLC. | $126.26 | 2021-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.20 | 2021-2024 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.17 | 2023-2024 | Xifaxan |
| Medtronic, INC. | $44.50 | 2022 | |
| Abbott Laboratories | $43.51 | 2024-2025 | Freestyle Libre 3 |
| Abbvie INC. | $39.45 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $35.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $28.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.34 | 2021 | |
| Ibsa Pharma INC. | $23.73 | 2022 | |
| Boston Scientific Corporation | $23.71 | 2023 | Watchman Flx |
| Inogen, INC. | $23.33 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Astellas Pharma US INC | $21.08 | 2024 | Veozah |
| Dexcom, INC. | $19.71 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $18.35 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $17.00 | 2022 | |
| Lundbeck LLC | $16.55 | 2024 | Rexulti |
| Corcept Therapeutics | $16.22 | 2025 | Korlym |
| Hikma Pharmaceuticals USA | $14.74 | 2023 | Ryaltris, Mitigare |
| Biohaven Pharmaceuticals, INC. | $14.71 | 2021 | |
| Eisai INC. | $14.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.